Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvimopan in Opioid-Induced Postoperative Bowel Dysfunction
NCT00388479Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2001
- Primary completion
- Nov 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alvimopan in postoperative ileus (POI) (3 arms), sponsored by Merck & Co. Primary endpoint: Acceleration of gastrointestinal recovery. Started Dec 2001; status: completed.
02
Drugs
alvimopan
03
Conditions
postoperative ileus (POI)
Beyond the preview
Go deeper on NCT00388479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00388479.